175 related articles for article (PubMed ID: 15932006)
1. Pharmaceutical research and development and the patent system.
Love J
Int J Health Serv; 2005; 35(2):257-63. PubMed ID: 15932006
[TBL] [Abstract][Full Text] [Related]
2. Pfizer slashes R&D.
Cressey D
Nature; 2011 Feb; 470(7333):154. PubMed ID: 21307908
[No Abstract] [Full Text] [Related]
3. Value of pharmaceuticals: ensuring the future of research and development.
Serajuddin HK; Serajuddin AT
J Am Pharm Assoc (2003); 2006; 46(4):511-6. PubMed ID: 16913396
[TBL] [Abstract][Full Text] [Related]
4. Outlook: the profit problem in antibiotic R&D.
Nathan C; Goldberg FM
Nat Rev Drug Discov; 2005 Nov; 4(11):887-91. PubMed ID: 16247440
[TBL] [Abstract][Full Text] [Related]
5. Patent reform in the US: what's at stake for pharmaceutical innovation?
Yancey A; Stewart CN
Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
[TBL] [Abstract][Full Text] [Related]
6. The roles of patents and research and development incentives in biopharmaceutical innovation.
Grabowski HG; DiMasi JA; Long G
Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
[TBL] [Abstract][Full Text] [Related]
7. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
Arnold DG; Troyer JL
J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
[TBL] [Abstract][Full Text] [Related]
8. [Corrupt research may damage public health].
Waldum HL
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2672-3. PubMed ID: 16215620
[No Abstract] [Full Text] [Related]
9. A free market solution for prescription drug crises.
Baker D
Int J Health Serv; 2004; 34(3):517-26. PubMed ID: 15346683
[TBL] [Abstract][Full Text] [Related]
10. An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry.
Winther FO; Hole OP; Nitter-Hauge S
Eur J Clin Pharmacol; 2007 Oct; 63(10):909-12. PubMed ID: 17673994
[TBL] [Abstract][Full Text] [Related]
11. Big Pharma's Commedia.
Steele FR
Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
[No Abstract] [Full Text] [Related]
12. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
Barton JH; Emanuel EJ
JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
[TBL] [Abstract][Full Text] [Related]
13. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
Dimitri N
Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical industry must take its medicine.
Macilwain C
Nature; 2011 Feb; 470(7333):141. PubMed ID: 21307893
[No Abstract] [Full Text] [Related]
15. Medical ethics, research and the pharmaceutical industry.
Abud-Mendoza C
Reumatol Clin; 2012; 8(5):233-5. PubMed ID: 22608694
[No Abstract] [Full Text] [Related]
16. The people vs patents.
New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337
[No Abstract] [Full Text] [Related]
17. Importancia de la investigación clínica independiente en la medicina: dificultades y recomendaciones.
Arrieta O; Campillo C; Burgos R; Celis MÁ; Llata M; Domínguez J; Halabe J; Islas S; Jasso L; Lifshitz A; Moreno M; Plancarte R; Reyes-Sánchez A; Ruiz-Argüelles GJ; Soda A; Verástegui E; Sotelo J
Gac Med Mex; 2019; 155(3):319-321. PubMed ID: 31219475
[TBL] [Abstract][Full Text] [Related]
18. A new prize system for drug innovation.
Gandjour A; Chernyak N
Health Policy; 2011 Oct; 102(2-3):170-7. PubMed ID: 21724290
[TBL] [Abstract][Full Text] [Related]
19. Excavating treasure from the amber of the prior art: why the public benefit doctrine is ill-suited to the pharmaceutical sciences.
Hess RA
Food Drug Law J; 2011; 66(1):105-20, iii. PubMed ID: 24505849
[TBL] [Abstract][Full Text] [Related]
20. Going over the patent cliff.
Schommer JC
Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
[No Abstract] [Full Text] [Related]
[Next] [New Search]
